Spotlight On... Tufts pegs R&D costs at $2.6B per drug; Tigenix raises $26M; and more...

Tufts University's Center for the Study of Drug Development updated its widely cited--and oft-disputed--estimates for how much it costs to take a drug from the lab to the pharmacy, tabbing the figure at about $2.6 billion. That number, averaged from 106 randomly selected products from 10 pharma companies, is 8.5% higher than the result of Tufts' prior survey, released in 2014. More

@FierceBiotech: Corvus shoots for $80M in an IPO to support its immuno-oncology pipeline. News | Follow @FierceBiotech

@JohnCFierce: Interesting to think that pointing out what Trump got wrong could become a full-time job for the next 4 years. More | Follow @JohnCFierce

> Belgian biotech Tigenix raised about $26 million in a private placement to support its in-development treatment for bowel disease. Story

> NantKwest ($NK) said it will have to restate its last two quarterly financial disclosures after identifying an accounting error related to stock compensation for Chairman and CEO Patrick Soon-Shiong. Item

Medical Device News

@FierceMedDev: FDA loss in Vascular Solution off-label promotion case foreshadowed Amarin settlement, Artlce | Follow @FierceMedDev

@VarunSaxena2: Hmmm... all the media bumpkins can say Rubio won again. This is all you need to know.  | Follow @VarunSaxena2

@EmilyWFierce: Apple plots smartphone-based medical device application for Apple Watch. Article | Follow @EmilyWFierce

> Boston Sci wins FDA approval of ablation catheter to treat atrial flutter. Story

Pharma News

@FiercePharma: BeiGene approved to start China leg of global BTK inhibitor trial. Story | Follow @FiercePharma

@EricPFierce: Vertex, committed to continuous manufacturing, has Hovione build plant to complement the one it already has. Story | Follow @EricPFierce

@CarlyHFierce: Perrigo execs collect $2.75M in bonuses for fending off Mylan takeover. More | Follow @CarlyHFierce

> EMA puts Gilead's Zydelig under the lens after deaths crop up in trials. Article

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”